Studies Advance Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology for Significantly Improving Pharmaceutical Drugs
- Lexaria Bioscience is dedicated to applying its patented technology to pharmaceutical drug offerings to enhance their performance and speed their rate of effective use
- The company’s flagship DehydraTECH(TM) technology has delivered numerous successes in studies of its potential for treating high blood pressure and heart disease, nicotine addiction, and virus infection
- Most recently, the company reported successes in increasing the speed and effectiveness in a drug treating erectile dysfunction (“ED”) in laboratory animals
- Lexaria is preparing an investigational new drug (“IND”) application for its hypertension line of study with the aim of achieving a new drug application (“NDA”) approval from the FDA
The recent announcement that drug bio-effectiveness innovator Lexaria Bioscience’s (NASDAQ: LEXX) patented DehydraTECH(TM) technology may be useful in erectile dysfunction therapy by enhancing the speed of effectiveness of medication sildenafil (common as Viagra) follows on a number of developmental successes reported by Lexaria.
DehydraTECH is a proprietary technology that changes how the body detects and absorbs drugs by combining active pharmaceutical ingredients (“APIs”) with a fatty acid oil, applying it to a food or other type of carrier particle, synthesizing it through a dehydration procedure and rendering the resulting powder or liquid as a final product capable of being rapidly absorbed by the body without suffering reduced effectiveness through filtration by the body’s liver and digestive system.
Lexaria’s testing has focused on four basic areas of application — improving the treatment of heart disease and high blood pressure, delivering nicotine in a non-smoke form, improving the effectiveness of antiviral drugs and making CBD from hemp rapidly available without inhalation.
During the company’s 2021-2022 study program (https://nnw.fm/trac9) a number of successes have been reported. In the HYPER-A21-1 and 2 studies the company demonstrated enhancement in the amount of CBD delivered to lab animals’ bloodstreams and brain tissue, the HYPER-H21-1 and 2 studies showed improved blood pressure reduction and reduction of blood vessel stiffness in humans, and NIC-A21-1 revealed oral nicotine delivery peak levels that were 10 to 20 times faster and 10 times higher than those of the control substances.
The series VIRAL-C21-3, VIRAL-A20-2, VIRAL-MC21-1, and VIRAL-A20-3 showed inhibition of the COVID-19/SARS-CoV-2 virus, increased drug availability, and potential FDA-compliant prevention of new molecular entity (“NME”) creation utilizing antiviral drugs Remdesivir, Ebastine and Colchicine.
“Lexaria’s technology is best thought of as an additional layer that companies offering consumer supplements, prescription and non-prescription based drugs, and nicotine products can utilize to improve the effectiveness of their existing or planned new products,” the company’s website states (https://nnw.fm/MI98i). “Lexaria licenses its advanced technology to other companies around the world to offer consumers the best performance possible across an array of product formats.”
Currently, all of the company’s operations are fully funded through the second quarter of 2023. Revenues grew more than 150 percent between 2020 and 2021 as Lexaria uplisted to the Nasdaq Capital Markets.
The DehydraTECH-CBD human studies for treating hypertension are the most advanced as the company is in preparations for an investigational new drug (“IND”) application with the aim of filing for a new drug application (“NDA”) with the FDA.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria Bioscience is dedicated to applying its patented technology to pharmaceutical drug offerings to enhance their performance and speed their rate of effective use
- The company’s flagship DehydraTECH(TM) technology has delivered numerous successes in studies of its potential for treating high blood pressure and heart disease, nicotine addiction, and virus infection
- Most recently, the company reported successes in increasing the speed and effectiveness in a drug treating erectile dysfunction (“ED”) in laboratory animals
- Lexaria is preparing an investigational new drug (“IND”) application for its hypertension line of study with the aim of achieving a new drug application (“NDA”) approval from the FDA
The recent announcement that drug bio-effectiveness innovator Lexaria Bioscience’s (NASDAQ: LEXX) patented DehydraTECH(TM) technology may be useful in erectile dysfunction therapy by enhancing the speed of effectiveness of medication sildenafil (common as Viagra) follows on a number of developmental successes reported by Lexaria.
DehydraTECH is a proprietary technology that changes how the body detects and absorbs drugs by combining active pharmaceutical ingredients (“APIs”) with a fatty acid oil, applying it to a food or other type of carrier particle, synthesizing it through a dehydration procedure and rendering the resulting powder or liquid as a final product capable of being rapidly absorbed by the body without suffering reduced effectiveness through filtration by the body’s liver and digestive system.
Lexaria’s testing has focused on four basic areas of application — improving the treatment of heart disease and high blood pressure, delivering nicotine in a non-smoke form, improving the effectiveness of antiviral drugs and making CBD from hemp rapidly available without inhalation.
During the company’s 2021-2022 study program (https://nnw.fm/trac9) a number of successes have been reported. In the HYPER-A21-1 and 2 studies the company demonstrated enhancement in the amount of CBD delivered to lab animals’ bloodstreams and brain tissue, the HYPER-H21-1 and 2 studies showed improved blood pressure reduction and reduction of blood vessel stiffness in humans, and NIC-A21-1 revealed oral nicotine delivery peak levels that were 10 to 20 times faster and 10 times higher than those of the control substances.
The series VIRAL-C21-3, VIRAL-A20-2, VIRAL-MC21-1, and VIRAL-A20-3 showed inhibition of the COVID-19/SARS-CoV-2 virus, increased drug availability, and potential FDA-compliant prevention of new molecular entity (“NME”) creation utilizing antiviral drugs Remdesivir, Ebastine and Colchicine.
“Lexaria’s technology is best thought of as an additional layer that companies offering consumer supplements, prescription and non-prescription based drugs, and nicotine products can utilize to improve the effectiveness of their existing or planned new products,” the company’s website states (https://nnw.fm/MI98i). “Lexaria licenses its advanced technology to other companies around the world to offer consumers the best performance possible across an array of product formats.”
Currently, all of the company’s operations are fully funded through the second quarter of 2023. Revenues grew more than 150 percent between 2020 and 2021 as Lexaria uplisted to the Nasdaq Capital Markets.
The DehydraTECH-CBD human studies for treating hypertension are the most advanced as the company is in preparations for an investigational new drug (“IND”) application with the aim of filing for a new drug application (“NDA”) with the FDA.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
